Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A diffuse large B-cell lymphoma that is categorized as EZB with high probability by the LymphGen algorithm. This is based on a combination of genetic features and EZB DLBCLs often, but do not always, have hot spot mutations in EZH2 and/or a BCL2 translocation. This class can be further subdivided into two sub-classes EZB-MYC+ and EZB-MYC- using the double hit gene expression signature (DHITsig). This subgroup also commonly has mutations due to aberrant somatic hypermutation affecting IRF8, which can be coding or non-coding.
Biomarker and diagnostic research for EZB diffuse large B-cell lymphoma has been reported in the published literature.
No clinical trials have been registered for EZB diffuse large B-cell lymphoma.
19 publications have been identified in PubMed for EZB diffuse large B-cell lymphoma. Research spans Diagnostic / Biomarker (32%), Basic Science / Preclinical (32%), and Review / Meta-Analysis (11%).
Research Type | Count | % of Total |
|---|---|---|
Testing and diagnosis research | 6 | 32% |
Data assembled from 2 of 12 sources · Last updated Sep 19, 2026, 6:43 AM UTC
Common questions about EZB diffuse large B-cell lymphoma
Laboratory research
6 |
32% |
Research summaries | 2 | 11% |
Clinical study results | 2 | 11% |
Patient case studies | 1 | 5% |
Disease patterns and progression | 1 | 5% |
New treatment approaches | 1 | 5% |
Uppal M (2026). [PMID: 42054619](https://pubmed.ncbi.nlm.nih.gov/42054619/). *J Clin Oncol*. [Review / Meta-Analysis]
Yim J (2026). [PMID: 41544233](https://pubmed.ncbi.nlm.nih.gov/41544233/). *Blood Adv*. [Diagnostic / Biomarker]
Jing Z (2025). [PMID: 41170601](https://pubmed.ncbi.nlm.nih.gov/41170601/). *Curr Med Res Opin*. [Case Report / Case Series]
Tatterton DJ (2025). [PMID: 40896832](https://pubmed.ncbi.nlm.nih.gov/40896832/). *Blood*. [Review / Meta-Analysis]
Arnason JE (2025). [PMID: 40902079](https://pubmed.ncbi.nlm.nih.gov/40902079/). *Blood Adv*. [Clinical Trial Publication]
Zhao P (2025). [PMID: 39641321](https://pubmed.ncbi.nlm.nih.gov/39641321/). *Hematol Oncol*. [Epidemiology / Natural History]
Wang Y (2025). [PMID: 41260205](https://pubmed.ncbi.nlm.nih.gov/41260205/). *Cell Rep Med*. [Diagnostic / Biomarker]
Wu YF (2025). [PMID: 39492801](https://pubmed.ncbi.nlm.nih.gov/39492801/). *Cancer Sci*. [Diagnostic / Biomarker]
Yeh YC (2025). [PMID: 40774060](https://pubmed.ncbi.nlm.nih.gov/40774060/). *Pathol Res Pract*. [Basic Science / Preclinical]
Wang H (2025). [PMID: 40247210](https://pubmed.ncbi.nlm.nih.gov/40247210/). *BMC Cancer*. [Basic Science / Preclinical]